The need for more advanced and accurate analysis methods for tissue samples in drug development, scientific research, and clinical diagnostics is driven by an aging population, the increasing prevalence of cancer and chronic diseases, and the development of more potent and precise medications. To better understand diseases, identify the right drug candidates in the development phase, and enable early diagnosis and personalized treatment, advanced methods are required. These methods must be capable of measuring extremely low levels and distinguishing very small differences in biological substances (so-called biomarkers) in tissue samples. The global tissue diagnostics market is expected to reach USD 7.3 billion by 2027, with a 6.6% growth rate over five years.
Lumito has developed next-generation tissue analysis within digital pathology. The unique and patented technology enables extremely sensitive measurements. Tissue analysis is a central method for ensuring that drugs are developed efficiently and safely. In today’s drug development, comparisons between different drug candidates are often based on visual assessments of tissue samples. With Lumito ‘s product, these analyses become both more precise and measurable, enabling increased objectivity in assessments and, therefore, greater reliability in decision-making. Lumito’s product generates high-resolution digital images that have great potential to facilitate the integration and use of AI in tissue analysis. Lumito aims to immediately contribute to saving lives by helping drug development companies create better and more personalized medicines faster. The patented technology that Lumito uses has great potential in clinical diagnostics, where detecting diseases earlier and monitoring the effects of treatments relies on the ability to measure the lowest possible levels of biological markers. Lumito plans to make the unique strengths of this technology available for clinical decisions through a future product for diagnostic use.
To achieve efficiency and flexibility in the development of new drugs, a significant portion of the work is currently outsourced by pharmaceutical companies to CROs (Contract Research Organizations), making CROs a key player in drug development. Lumito primarily focuses on partnerships with European CROs to enable them to offer tissue analyses based on Lumito’s solution to their end customers. Lumito intends to transfer several existing tests to the company’s product Scizys through collaborative projects with CROs, as well as develop new tests based on the product’s unique strengths. Since CROs offer their tests to many end customers, Lumito creates an efficient business model from both a sales and cost perspective, as the CROs effectively act as Lumito’s distribution channel. Lumito also targets larger international pharmaceutical and diagnostics companies, as well as academic research groups. International expansion and the future offering of a clinical diagnostic product are part of the company’s strategy.
Lumito’s board, team, and external advisors are deeply committed to the company, with profound specialist knowledge and extensive experience in product development, commercialization, and business development. This fosters a “can-do” attitude, internal efficiency, and strong credibility in customer relationships and partnerships. Lumito is a spin-off from Lund University and, with its continued base in Lund and Medicon Village, is situated in the heart of a thriving innovation hub with close proximity to both academic research and infrastructure for new, innovative start-up companies in Life Science. The team and location in Lund and the Öresund region provide the company with excellent conditions to succeed in its vision of becoming a world leader in quantitative analysis for digital pathology, continually delivering valuable solutions for the healthcare of tomorrow.
Phone: +46(0)10-204 00 15
Mail: info@lumito.se
Lumito AB (publ)
Scheelevägen 19, SE-223 63 Lund, Sweden